Neurocrine signs $400M-plus deal with Idorsia for epilepsy drugSwiss biotech Idorsia and Neurocrine Biosciences of the US have amended a deal signed last year to develop Share XNeurocrine signs $400M-plus deal with Idorsia for epilepsy drughttps://pharmaphorum.com/news/neurocrine-signs-400m-plus-deal-with-idorsia-for-epilepsy-drug/
Neurocrine and Xenon agree $1.75bn epilepsy R&D tie-upTwo biotechs, Neurocrine Biosciences and Xenon, have announced a licence and collaboration agreement to develop first-in-class treatments for Share XNeurocrine and Xenon agree $1.75bn epilepsy R&D tie-uphttps://pharmaphorum.com/news/neurocrine-and-xenon-agree-1-75bn-epilepsy-rd-tie-up/
GW Pharma’s cannabis-derived epilepsy drug approved in EUGW Pharmaceuticals’ cannabis-derived drug Epidyolex has been approved in Europe for two kinds of rare childhood epilepsy. The Share XGW Pharma’s cannabis-derived epilepsy drug approved in EUhttps://pharmaphorum.com/news/gw-pharmas-cannabis-derived-epilepsy-drug-approved-in-eu/
GW confident epilepsy drug will get NHS funding despite NICE rejectionThe UK’s GW Pharma has insisted there will be no repeat of the controversy seen with cystic fibrosis Share XGW confident epilepsy drug will get NHS funding despite NICE rejectionhttps://pharmaphorum.com/news/no-repeat-of/
Pfizer’s Lyrica fails phase 3 trial in epilepsyPfizer’s Lyrica has failed to meet its primary endpoint in a phase 3 trial in primary generalised tonic-clonic Share XPfizer’s Lyrica fails phase 3 trial in epilepsyhttps://pharmaphorum.com/news/pfizers-lyrica-fails-phase-3-trial-in-epilepsy/
Zogenix slumps after FDA refuses epilepsy drug fileZogenix’s only drug candidate is facing a long delay after the FDA refused to accept its marketing application, Share XZogenix slumps after FDA refuses epilepsy drug filehttps://pharmaphorum.com/news/zogenix-slumps-after-fda-refuses-epilepsy-drug-file/
Medicinal cannabis seizure prompts urgent question in ParliamentHealth secretary Matt Hancock responded to an urgent question tabled by Conservative MP Sir Mike Penning yesterday, following Share XMedicinal cannabis seizure prompts urgent question in Parliamenthttps://pharmaphorum.com/news/medicinal-cannabis-seizure-prompts-urgent-question-in-parliament/
UCB joins with UK charity to research new epilepsy drugsBelgium’s UCB has joined forces with the UK’s Epilepsy Society in a collaboration aimed at finding treatments for Share XUCB joins with UK charity to research new epilepsy drugshttps://pharmaphorum.com/news/ucb-joins-with-uk-charity-to-research-new-epilepsy-drugs/
NHS U-turns on Afinitor for TSC-related epilepsyNHS England has reversed a previous decision and will be funding Novartis’ Afinitor (everolimus) for TSC-related refractory epilepsy Share XNHS U-turns on Afinitor for TSC-related epilepsyhttps://pharmaphorum.com/news/nhs-u-turns-afinitor-tsc-related-epilepsy/
